Optimization of downstream recovery and stabilization of drug substance of an intranasal influenza vaccine

Active Project Grant Awarded Last action

Award ID
HT94252410233
Recipient
Awarding agency
Obligated
$6,237,445

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 86% complete
Place of performance
Madison, WI 53711, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants from the Defense Health Agency and National Institute of Allergy and Infectious Diseases to advance the development of scalable manufacturing, toxicity testing, and clinical evaluation of their proprietary M2SR influenza vaccine technology. The goal is to transform influenza prevention through novel intranasal and monovalent vaccine candidates.

Quick answers

Who received award HT94252410233?

HT94252410233 was awarded to Flugen Inc. by Defense Health Agency (Department of Defense) on April 1, 2024.

How much is award HT94252410233 worth?

$6,237,445 has been obligated on HT94252410233.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login